{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:15:29Z","timestamp":1787019329472,"version":"build-2736575974"},"reference-count":47,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"national institutes of health","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Donor funds from Jamie\u2019s Hope, Mr. and Mrs. Zane W. Arrott, and Mr. and Mrs. Steven McKenzie for Dr. Tsimberidou\u2019s Personalized Medicine Program"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Patients with advanced and\/or metastatic solid tumors have limited treatment options. Mutations that serve as biomarkers of carcinogenesis can be found in cell-free DNA of patients\u2019 plasma. Analysis of circulating tumor DNA (ctDNA) was developed as a non-invasive, cost-effective alternative to tumor biopsy when such biopsy is not technically feasible or it is associated with high risk for complications. The role of ctDNA in precision oncology is promising but its clinical significance across tumor types remains to be validated. We report a case series of three heavily pretreated patients with advanced solid tumors who received matched targeted therapy based on ctDNA analysis and\/or tumor molecular profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation:<\/jats:title>\n                    <jats:p>Three patients with advanced, metastatic cancer and the following characteristics are presented: a 71-year-old woman with ovarian cancer and BRCA2 mutation identified in ctDNA and tumor tissue was treated with a PARP inhibitor and achieved partial response by RECIST (Response Evaluation Criteria in Solid Tumors) for 22.6+ months; a 40-year-old woman with adenoid cystic carcinoma of the parotid gland was treated with a MEK\/RAF pathway inhibitor on the basis of RAF1 amplification on ctDNA analysis and had stable disease for 20.2\u2009months; and a 56-year-old woman with breast cancer and a BRCA1 mutation identified by ctDNA analysis was treated with a PARP inhibitor and achieved stable disease for 9.1\u2009months. All three patients are alive at the time of this report.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These results suggest that ctDNA analysis can contribute to selection of targeted therapy in patients with advanced, metastatic cancer. Prospective clinical trials to evaluate and optimize ctDNA biomarkers, as well as the integration of novel and\/or alternative targeted therapies, are warranted to fully assess the role of ctDNA analysis in cancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>www.clinicaltrials.gov (NCT02152254). Registered May 28, 2014. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02152254 . MD Anderson protocol # PA12-1161 (approval ID IRB1 FWA00000121) and # PA11-0377 (approval ID IRB4 FWA00005015).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359211001538","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T08:08:05Z","timestamp":1616573285000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Prolonged response to treatment based on cell-free DNA analysis and molecular profiling in three patients with metastatic cancer: a case series"],"prefix":"10.1177","volume":"13","author":[{"given":"Mohammad Faraz","family":"Naqvi","sequence":"first","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Hiep","family":"Vo","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vining","sequence":"additional","affiliation":[{"name":"Department of Abdominal Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-233X","authenticated-orcid":false,"given":"Apostolia-Maria","family":"Tsimberidou","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Unit 455, 1515 Holcombe Boulevard, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,3,24]]},"reference":[{"key":"bibr1-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000393"},{"key":"bibr2-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1016\/j.crad.2020.09.024"},{"key":"bibr3-17588359211001538","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27418"},{"key":"bibr4-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.66.7162"},{"key":"bibr5-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3511"},{"key":"bibr6-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2419"},{"key":"bibr7-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0532-T"},{"key":"bibr8-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1436"},{"key":"bibr9-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1172\/JCI72763"},{"key":"bibr10-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.148.4.791"},{"key":"bibr11-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401720"},{"key":"bibr12-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1162"},{"key":"bibr13-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(04)00215-6"},{"key":"bibr14-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1186\/1477-3163-3-6"},{"key":"bibr15-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2670"},{"key":"bibr16-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27709"},{"key":"bibr17-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0799"},{"key":"bibr18-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25893"},{"key":"bibr19-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-0646"},{"key":"bibr20-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118210"},{"key":"bibr21-17588359211001538","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11635"},{"key":"bibr22-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp186"},{"key":"bibr23-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2223"},{"key":"bibr24-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789"},{"key":"bibr25-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx112"},{"key":"bibr26-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0457-y"},{"key":"bibr27-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2017.07.004"},{"key":"bibr28-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx118"},{"key":"bibr29-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0824-4"},{"key":"bibr30-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.414"},{"key":"bibr31-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12391"},{"key":"bibr32-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-0399"},{"key":"bibr33-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac7551"},{"key":"bibr34-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1283"},{"key":"bibr35-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/nature12065"},{"key":"bibr36-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.04.003"},{"key":"bibr37-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1372"},{"key":"bibr38-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1324"},{"key":"bibr39-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2585"},{"key":"bibr40-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0380-z"},{"key":"bibr41-17588359211001538","unstructured":"U. S. Food and Drug Administration. FDA approves first liquid biopsy next-generation sequencing companion diagnostic test, https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-liquid-biopsy-next-generation-sequencing-companion-diagnostic-test (2020, accessed 11 January 2021)."},{"key":"bibr42-17588359211001538","unstructured":"U. S. Food and Drug Administration. FDA approves liquid biopsy NGS companion diagnostic test for multiple cancers and biomarkers, https:\/\/www.fda.gov\/drugs\/fda-approves-liquid-biopsy-ngs-companion-diagnostic-test-multiple-cancers-and-biomarkers (2020, accessed 11 January 2021)."},{"key":"bibr43-17588359211001538","unstructured":"Targeted Agent and Profiling Utilization Registry (TAPURTM) study, https:\/\/www.tapur.org\/ (2020, accessed 30 July 2020)."},{"key":"bibr44-17588359211001538","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.16.00059","volume":"1","author":"Kim ST","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"bibr45-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0621"},{"key":"bibr46-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx125"},{"key":"bibr47-17588359211001538","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy061"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211001538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359211001538","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359211001538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:25:40Z","timestamp":1777587940000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359211001538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":47,"alternative-id":["10.1177\/17588359211001538"],"URL":"https:\/\/doi.org\/10.1177\/17588359211001538","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"article-number":"17588359211001538"}}